Please login to the form below

Not currently logged in
Email:
Password:

crizotinib

This page shows the latest crizotinib news and features for those working in and with pharma, biotech and healthcare.

Pfizer’s Talzenna cleared for breast cancer in Europe

Pfizer’s Talzenna cleared for breast cancer in Europe

The latest approval is another pillar in its bid to rebuild its oncology franchise that has been hit hard by competition to Xalkori (crizotinib) for ALK-positive NSCLC from Roche’s

Latest news

More from news
Approximately 10 fully matching, plus 56 partially matching documents found.

Latest Intelligence

  • Oncology drugs under AMNOG: part two Oncology drugs under AMNOG: part two

    Xalkori: Symptom improvement and quality of life gains add benefit. In the case of Xalkori (crizotinib), Pfizer's product targeting a subsegment of non-small cell lung cancer (NSCLC) in which ... Outcome. Xalkori(crizotinib) in NSCLC. No OS benefit shown

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Fishawack Group of Companies

The Fishawack Group of Companies is one of the largest independent medical communications and medical marketing specialists, with teams in...

Latest intelligence

The 2019 WHO essential medicine list: Narrowing the access gap to innovative cancer treatments
The essential medicine list (EML) contains treatments considered to be the most effective and safe in targeting global health concerns. On 9 July 2019, the World Health Organization (WHO) published...
NICE
Evolution or revolution: the latest review of NICE methods
By Leela Barham...
PRO
Integrating patient reported outcomes into clinical trials
How capturing the patient voice is unlocking medicines’ commercial potential...

Infographics